Logo image of PEPG

PEPGEN INC (PEPG) Stock Price, Quote, News and Overview

NASDAQ:PEPG - Nasdaq - US7133171055 - Common Stock - Currency: USD

1.495  +0.06 (+3.82%)

PEPG Quote, Performance and Key Statistics

PEPGEN INC

NASDAQ:PEPG (5/22/2025, 1:48:53 PM)

1.495

+0.06 (+3.82%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High19.3
52 Week Low0.88
Market Cap48.92M
Shares32.72M
Float31.06M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06
IPO05-06 2022-05-06


PEPG short term performance overview.The bars show the price performance of PEPG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

PEPG long term performance overview.The bars show the price performance of PEPG in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PEPG is 1.495 USD. In the past month the price decreased by -10.56%. In the past year, price decreased by -90.11%.

PEPGEN INC / PEPG Daily stock chart

PEPG Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.8 323.39B
AMGN AMGEN INC 13.07 145.94B
GILD GILEAD SCIENCES INC 13.79 132.92B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.25B
REGN REGENERON PHARMACEUTICALS 13.5 64.57B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.80B
ARGX ARGENX SE - ADR 99.04 35.50B
ONC BEIGENE LTD-ADR 5.93 25.73B
BNTX BIONTECH SE-ADR N/A 23.74B
NTRA NATERA INC N/A 20.85B
SMMT SUMMIT THERAPEUTICS INC N/A 19.47B
BIIB BIOGEN INC 8.01 18.56B

About PEPG

Company Profile

PEPG logo image PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. The company also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Company Info

PEPGEN INC

245 Main St, 2nd Floor

Cambridge MASSACHUSETTS US

Employees: 72

PEPG Company Website

PEPG Investor Relations

Phone: 17034568000

PEPGEN INC / PEPG FAQ

What is the stock price of PEPGEN INC today?

The current stock price of PEPG is 1.495 USD. The price increased by 3.82% in the last trading session.


What is the ticker symbol for PEPGEN INC stock?

The exchange symbol of PEPGEN INC is PEPG and it is listed on the Nasdaq exchange.


On which exchange is PEPG stock listed?

PEPG stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PEPGEN INC stock?

11 analysts have analysed PEPG and the average price target is 12.44 USD. This implies a price increase of 732.37% is expected in the next year compared to the current price of 1.495. Check the PEPGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PEPGEN INC worth?

PEPGEN INC (PEPG) has a market capitalization of 48.92M USD. This makes PEPG a Nano Cap stock.


How many employees does PEPGEN INC have?

PEPGEN INC (PEPG) currently has 72 employees.


What are the support and resistance levels for PEPGEN INC (PEPG) stock?

PEPGEN INC (PEPG) has a support level at 1.39 and a resistance level at 1.59. Check the full technical report for a detailed analysis of PEPG support and resistance levels.


Should I buy PEPGEN INC (PEPG) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PEPGEN INC (PEPG) stock pay dividends?

PEPG does not pay a dividend.


When does PEPGEN INC (PEPG) report earnings?

PEPGEN INC (PEPG) will report earnings on 2025-08-06.


What is the Price/Earnings (PE) ratio of PEPGEN INC (PEPG)?

PEPGEN INC (PEPG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.13).


What is the Short Interest ratio of PEPGEN INC (PEPG) stock?

The outstanding short interest for PEPGEN INC (PEPG) is 7.2% of its float. Check the ownership tab for more information on the PEPG short interest.


PEPG Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PEPG Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PEPG. The financial health of PEPG is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PEPG Financial Highlights

Over the last trailing twelve months PEPG reported a non-GAAP Earnings per Share(EPS) of -3.13. The EPS increased by 3.33% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -80.2%
ROE -111.28%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-46.03%
Sales Q2Q%N/A
EPS 1Y (TTM)3.33%
Revenue 1Y (TTM)N/A

PEPG Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to PEPG. The Buy consensus is the average rating of analysts ratings from 11 analysts.


Ownership
Inst Owners92.28%
Ins Owners0.02%
Short Float %7.2%
Short Ratio5.78
Analysts
Analysts83.64
Price Target12.44 (732.11%)
EPS Next Y4.68%
Revenue Next YearN/A